ecovyst inc - ECVT
ECVT
Close Chg Chg %
10.10 0.16 1.53%
Pre-Market
10.26
+0.16 (1.53%)
Volume: 1.07M
Last Updated:
Sep 9, 2026, 3:59 PM EDT
Company Overview: ecovyst inc - ECVT
ECVT Key Data
| Open $10.21 | Day Range 10.21 - 10.36 |
| 52 Week Range 7.50 - 15.09 | Market Cap $1.12B |
| Shares Outstanding 109.47M | Public Float 106.94M |
| Beta 1.08 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.55 |
| Yield 0.00% | Dividend $3.20 |
| EX-DIVIDEND DATE Aug 11, 2021 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.25M |
ECVT Performance
| 1 Week | 0.39% | ||
| 1 Month | -1.35% | ||
| 3 Months | -21.70% | ||
| 1 Year | 10.81% | ||
| 5 Years | -17.41% |
ECVT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About ecovyst inc - ECVT
Ecovyst, Inc. engages in providing virgin and regenerated sulfuric acid products and services. It offers regenerated sulfuric acid, hazardous waste treatment services, virgin sulfuric acid for mining, virgin sulfuric acid derivatives for industrial production, virgin sulfuric acid derivatives for nylon production, catalyst activation, aluminum sulfate solution, and ammonium bisulfite solution. The company was founded in 1831 and is headquartered in Wayne, PA.
ECVT At a Glance
Ecovyst, Inc.
600 Lee Road
Wayne, Pennsylvania 19087
| Phone | 1-484-617-1200 | Revenue | 723.52M | |
| Industry | Chemicals: Specialty | Net Income | -22,291,000.00 | |
| Sector | Process Industries | 2025 Sales Growth | 2.7% | |
| Fiscal Year-end | 12 / 2026 | Employees | 617 | |
| View SEC Filings |
ECVT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.559 |
| Price to Book Ratio | 1.803 |
| Price to Cash Flow Ratio | 8.04 |
| Enterprise Value to EBITDA | 8.672 |
| Enterprise Value to Sales | 1.882 |
| Total Debt to Enterprise Value | 0.316 |
ECVT Efficiency
| Revenue/Employee | 1,172,633.712 |
| Income Per Employee | -36,128.039 |
| Receivables Turnover | 8.481 |
| Total Asset Turnover | 0.472 |
ECVT Liquidity
| Current Ratio | 2.643 |
| Quick Ratio | 2.422 |
| Cash Ratio | 1.632 |
ECVT Profitability
| Gross Margin | 20.657 |
| Operating Margin | 10.84 |
| Pretax Margin | 3.564 |
| Net Margin | -3.081 |
| Return on Assets | 0.411 |
| Return on Equity | 0.964 |
| Return on Total Capital | 0.608 |
| Return on Invested Capital | 0.483 |
ECVT Capital Structure
| Total Debt to Total Equity | 71.381 |
| Total Debt to Total Capital | 41.651 |
| Total Debt to Total Assets | 34.159 |
| Long-Term Debt to Equity | 69.808 |
| Long-Term Debt to Total Capital | 40.732 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ecovyst Inc - ECVT
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 820.16M | 691.12M | 704.49M | 723.51M | |
Sales Growth
| +34.19% | -15.73% | +1.94% | +2.70% | |
Cost of Goods Sold (COGS) incl D&A
| 606.09M | 503.72M | 513.56M | 574.05M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 79.16M | 84.60M | 89.36M | 78.60M | |
Depreciation
| 65.12M | 70.55M | 75.28M | 67.81M | |
Amortization of Intangibles
| 14.04M | 14.05M | 14.08M | 10.79M | |
COGS Growth
| +36.24% | -16.89% | +1.95% | +11.78% | |
Gross Income
| 214.07M | 187.40M | 190.94M | 149.46M | |
Gross Income Growth
| +28.69% | -12.46% | +1.89% | -21.72% | |
Gross Profit Margin
| +26.10% | +27.12% | +27.10% | +20.66% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 85.33M | 79.22M | 83.88M | 66.02M | |
Research & Development
| 7.23M | 7.80M | 6.81M | 12.16M | |
Other SG&A
| 78.10M | 71.42M | 77.06M | 53.86M | |
SGA Growth
| -12.73% | -7.17% | +5.88% | -21.29% | |
Other Operating Expense
| 2.20M | 1.79M | 1.33M | 5.01M | |
Unusual Expense
| 18.55M | 5.61M | 74.84M | 13.71M | |
EBIT after Unusual Expense
| 107.98M | 100.79M | 30.88M | 64.72M | |
Non Operating Income/Expense
| 23.29M | 48.61M | (3.68M) | (12.94M) | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | 27.73M | 30.62M | 15.11M | |
Interest Expense
| 36.53M | 67.46M | 32.23M | 26.00M | |
Interest Expense Growth
| -0.03% | +84.65% | -52.23% | -19.34% | |
Gross Interest Expense
| 37.98M | 69.42M | 33.24M | 27.66M | |
Interest Capitalized
| 1.44M | 1.96M | 1.01M | 1.66M | |
Pretax Income
| 94.73M | 81.94M | (5.02M) | 25.79M | |
Pretax Income Growth
| +579.54% | -13.51% | -106.13% | +613.46% | |
Pretax Margin
| +11.55% | +11.86% | -0.71% | +3.56% | |
Income Tax
| 24.94M | 10.79M | 1.63M | 19.50M | |
Income Tax - Current - Domestic
| 21.31M | 25.34M | 8.73M | (12.71M) | |
Income Tax - Current - Foreign
| - | 1.98M | 2.52M | 822.00K | |
Income Tax - Deferred - Domestic
| 2.26M | (15.64M) | (9.80M) | 32.21M | |
Income Tax - Deferred - Foreign
| - | (604.00K) | (1.44M) | 1.87M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | 27.73M | 30.62M | 15.11M | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 69.80M | 71.15M | (6.65M) | 6.29M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 69.80M | 71.15M | (6.65M) | 6.29M | |
Net Income Growth
| +3,790.47% | +1.95% | -109.35% | +194.53% | |
Net Margin Growth
| +8.51% | +10.30% | -0.94% | +0.87% | |
Extraordinaries & Discontinued Operations
| - | - | - | (28.58M) | - |
Discontinued Operations
| - | - | - | (28.58M) | - |
Net Income After Extraordinaries
| 69.80M | 71.15M | (6.65M) | (22.29M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 69.80M | 71.15M | (6.65M) | (22.29M) | |
EPS (Basic)
| 0.5224 | 0.6011 | -0.057 | -0.1933 | |
EPS (Basic) Growth
| +363.71% | +15.07% | -109.48% | -239.12% | |
Basic Shares Outstanding
| 133.60M | 118.37M | 116.72M | 115.29M | |
EPS (Diluted)
| 0.5167 | 0.5955 | -0.057 | -0.1933 | |
EPS (Diluted) Growth
| +360.83% | +15.25% | -109.57% | -239.12% | |
Diluted Shares Outstanding
| 135.09M | 119.49M | 116.72M | 115.96M | |
EBITDA
| 205.70M | 190.99M | 195.09M | 157.03M | |
EBITDA Growth
| +41.62% | -7.15% | +2.14% | -19.51% | |
EBITDA Margin
| +25.08% | +27.64% | +27.69% | +21.70% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 14.80 | |
| Number of Ratings | 6 | Current Quarters Estimate | 0.213 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | 0.691 | |
| Last Quarter’s Earnings | 0.21 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.39 | Next Fiscal Year Estimate | 0.876 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 6 | 6 |
| Mean Estimate | 0.21 | 0.16 | 0.69 | 0.88 |
| High Estimates | 0.26 | 0.20 | 0.70 | 0.97 |
| Low Estimate | 0.19 | 0.09 | 0.67 | 0.77 |
| Coefficient of Variance | 11.32 | 23.42 | 1.59 | 7.65 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 3 | 4 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Ecovyst Inc - ECVT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ecovyst Inc - ECVT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 27, 2026 | Laurie A. Bergman See Remarks | 43,353 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 17, 2026 | Kurt J. Bitting See Remarks; Director | 698,382 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $3.04 per share | 2,123,081.28 |
| Mar 17, 2026 | Kurt J. Bitting See Remarks; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Kurt J. Bitting See Remarks; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Kurt J. Bitting See Remarks; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2026 | Kurt J. Bitting See Remarks; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 6, 2026 | Anna Cheng Catalano Director | 102,805 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | Michael P. Feehan See Remarks | 358,620 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.31 per share | 3,697,372.20 |
| Feb 6, 2026 | Michael P. Feehan See Remarks | 378,019 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | David A. Bradley Director | 107,999 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | Kevin Michael Fogarty Director | 215,998 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | Donald L. Althoff Director | 58,376 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | Joseph Steven Koscinski See Remarks | 584,732 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | Susan F. Ward Director | 97,660 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | Bryan K. Brown Director | 109,015 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 6, 2026 | Sarah Lorance Director | 63,150 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |